The adjusted global antiphospholipid syndrome score (aGAPSS)and the risk of recurrent thrombosis

Results from the APS ACTION cohort

APS ACTION

Research output: Contribution to journalArticle

Abstract

Objectives: To assess whether patients with antiphospholipid syndrome (APS)and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS)when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION)Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous)compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

Original languageEnglish (US)
JournalSeminars in Arthritis and Rheumatism
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Antiphospholipid Syndrome
Thrombosis
Antiphospholipid Antibodies
Registries
Venous Thrombosis
Recurrence
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Hyperlipidemias
Glycoproteins
Cross-Sectional Studies
Clinical Trials
Databases
Hypertension

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Cardiovascular
  • GAPSS
  • Risk stratification
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

@article{27cdd57616cc499c90492091364cc982,
title = "The adjusted global antiphospholipid syndrome score (aGAPSS)and the risk of recurrent thrombosis: Results from the APS ACTION cohort",
abstract = "Objectives: To assess whether patients with antiphospholipid syndrome (APS)and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS)when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION)Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous)compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Cardiovascular, GAPSS, Risk stratification, Thrombosis",
author = "{APS ACTION} and Massimo Radin and Savino Sciascia and Doruk Erkan and Vittorio Pengo and Tektonidou, {Maria G.} and Amaia Ugarte and Pierluigi Meroni and Lanlan Ji and Belmont, {H. Michael} and Hannah Cohen and {Ramires de Jes{\'u}s}, Guilherme and Branch, {D. Ware} and Fortin, {Paul R.} and Laura Andreoli and Michelle Petri and Esther Rodriguez and Ignasi Rodriguez-Pinto and Knight, {Jason S.} and Tatsuya Atsumi and Rohan Willis and Emilio Gonzalez and Rosario Lopez-Pedrera and {Rossi Gandara}, {Ana Paula} and {Borges Gualhardo Vendramini}, Margarete and Alessandra Banzato and Ecem Sevim and Medha Barbhaiya and Maria Efthymiou and Ian Mackie and Bertolaccini, {Maria Laura} and Danieli Andrade",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.semarthrit.2019.04.009",
language = "English (US)",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The adjusted global antiphospholipid syndrome score (aGAPSS)and the risk of recurrent thrombosis

T2 - Results from the APS ACTION cohort

AU - APS ACTION

AU - Radin, Massimo

AU - Sciascia, Savino

AU - Erkan, Doruk

AU - Pengo, Vittorio

AU - Tektonidou, Maria G.

AU - Ugarte, Amaia

AU - Meroni, Pierluigi

AU - Ji, Lanlan

AU - Belmont, H. Michael

AU - Cohen, Hannah

AU - Ramires de Jesús, Guilherme

AU - Branch, D. Ware

AU - Fortin, Paul R.

AU - Andreoli, Laura

AU - Petri, Michelle

AU - Rodriguez, Esther

AU - Rodriguez-Pinto, Ignasi

AU - Knight, Jason S.

AU - Atsumi, Tatsuya

AU - Willis, Rohan

AU - Gonzalez, Emilio

AU - Lopez-Pedrera, Rosario

AU - Rossi Gandara, Ana Paula

AU - Borges Gualhardo Vendramini, Margarete

AU - Banzato, Alessandra

AU - Sevim, Ecem

AU - Barbhaiya, Medha

AU - Efthymiou, Maria

AU - Mackie, Ian

AU - Bertolaccini, Maria Laura

AU - Andrade, Danieli

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: To assess whether patients with antiphospholipid syndrome (APS)and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS)when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION)Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous)compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

AB - Objectives: To assess whether patients with antiphospholipid syndrome (APS)and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS)when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION)Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous)compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Cardiovascular

KW - GAPSS

KW - Risk stratification

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85066284402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066284402&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2019.04.009

DO - 10.1016/j.semarthrit.2019.04.009

M3 - Article

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

ER -